Interpretation of differential item functioning analyses using external review.

Abstract:

:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers, to help interpret these results. The authors conducted a literature review of this topic to describe the current usage of external reviews alongside DIF analyses. It concentrated on studies of health-related quality of life instruments, but studies in other fields were also considered. Relatively few examples of blinded item reviews were identified, and these were mostly from educational studies. A case study using blinded bilingual reviewers alongside translation DIF analyses of a health-related quality of life instrument is described. Future researchers should consider conducting external item reviews alongside DIF analyses.

authors

Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

doi

10.1586/erp.10.22

subject

Has Abstract

pub_date

2010-06-01 00:00:00

pages

253-8

issue

3

eissn

1473-7167

issn

1744-8379

journal_volume

10

pub_type

杂志文章,评审
  • Symptom clusters in patients with metastatic cancer: a literature review.

    abstract::This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.12.41

    authors: Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

    更新日期:2012-10-01 00:00:00

  • Role of patient and public participation in health technology assessment and coverage decisions.

    abstract::Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.82

    authors: Menon D,Stafinski T

    更新日期:2011-02-01 00:00:00

  • Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.

    abstract:OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1411193

    authors: Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

    更新日期:2018-06-01 00:00:00

  • Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?

    abstract::The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.2.145

    authors: Orlewska E

    更新日期:2006-04-01 00:00:00

  • Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses.

    abstract:OBJECTIVES:To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). METHODS:Three systematic literature reviews were conducted in MEDLINE and Embase to capture all relevant publications reporting 1) the epidemiology of T2D and complications in T2D and 2) th...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1782748

    authors: Alzaid A,Ladrón de Guevara P,Beillat M,Lehner Martin V,Atanasov P

    更新日期:2020-07-20 00:00:00

  • The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

    abstract:BACKGROUND:Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1282316

    authors: Schepers J,Plaete J,De Bourdeaudhuij I,Annemans L,Simoens S

    更新日期:2017-08-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.

    abstract::Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.2014.861743

    authors: De Franco AC,Oldridge N

    更新日期:2014-02-01 00:00:00

  • Depression and health-related quality of life in patients with rheumatoid arthritis.

    abstract::Rheumatoid arthritis is a chronic inflammatory musculoskeletal disease with a prevalence rate of 1-3% in Western countries. In addition to limited physical function, rheumatoid arthritis patients also suffer from psychologic comorbidities. Depression in rheumatoid arthritis patients has been linked to disease outcomes...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.5.645

    authors: Nichol MB,Zhang L

    更新日期:2005-10-01 00:00:00

  • Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.

    abstract::It is a continual challenge trying to improve the quality of prescribing while concurrently trying to address increasing pharmaceutical development, utilization and expenditure. National and regional reforms and initiatives in Sweden have moderated growth in ambulatory drug expenditure to 2.7% per annum in recent year...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.9.1.65

    authors: Godman B,Wettermark B,Hoffmann M,Andersson K,Haycox A,Gustafsson LL

    更新日期:2009-02-01 00:00:00

  • Quality of life in cancer clinical trials: researchers, patients and policy makers.

    abstract::The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.11.84

    authors: Dormer L

    更新日期:2011-12-01 00:00:00

  • Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation.

    abstract::The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.1045883

    authors: Gater A,Kitchen H,Heron L,Pollard C,Håkan-Bloch J,Højbjerre L,Hansen BB,Strandberg-Larsen M

    更新日期:2015-01-01 00:00:00

  • Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

    abstract:BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2018.1476142

    authors: Grewal S,Ramsey S,Balu S,Carlson JJ

    更新日期:2018-08-01 00:00:00

  • Cost-effective approaches to influenza prevention and treatment.

    abstract::Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.2.141

    authors: Rothberg M

    更新日期:2005-04-01 00:00:00

  • A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease.

    abstract::Smoking cessation is the only strategy that has shown a lasting reduction in the decline of lung function in patients with chronic obstructive pulmonary disease. This study aims to evaluate the cost-effectiveness of smoking cessation interventions in patients with chronic obstructive pulmonary disease, to assess the q...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2015.1001976

    authors: Kirsch F

    更新日期:2015-04-01 00:00:00

  • Cost of treating otitis media in Australia.

    abstract:OBJECTIVE:Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). METHODS:Little Australia-w...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.6

    authors: Taylor PS,Faeth I,Marks MK,Del Mar CB,Skull SA,Pezzullo ML,Havyatt SM,Coates HL

    更新日期:2009-04-01 00:00:00

  • Promoting pan-European cancer research for the benefit of all cancer patients.

    abstract::The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/erp.12.32

    authors: Bean J,Bottomley A,Meunier F

    更新日期:2012-08-01 00:00:00

  • Measuring the costs and benefits of pharmaceutical expenditures.

    abstract::In response to concerns about the cost burden of medical care in general and rising pharmaceutical costs in particular, a number of recent studies have examined trends in pharmaceutical expenditures. These studies have reached apparently disparate conclusions about factors responsible for rising pharmaceutical costs a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2.5.467

    authors: Crown WH,Ling D,Berndt E

    更新日期:2002-10-01 00:00:00

  • Management and costs of severe psoriasis: the role of new biologics.

    abstract::It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.5.573

    authors: Feldman SR,Pearce DJ

    更新日期:2004-10-01 00:00:00

  • Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices.

    abstract:INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2016.1141679

    authors: Drost RM,Paulus AT,Ruwaard D,Evers SM

    更新日期:2017-02-01 00:00:00

  • Probabilistic choice models in health-state valuation research: background, theories, assumptions and applications.

    abstract::Interest is rising in measuring subjective health outcomes, such as treatment outcomes that are not directly quantifiable (functional disability, symptoms, complaints, side effects and health-related quality of life). Health economists in particular have applied probabilistic choice models in the area of health evalua...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.12.85

    authors: Arons AM,Krabbe PF

    更新日期:2013-02-01 00:00:00

  • Priority setting in health: origins, description and application of the Australian Assessing Cost-Effectiveness initiative.

    abstract::This article reports on the 'Assessing Cost-Effectiveness' (ACE) initiative in priority setting from Australia. It commences with why priority setting is topical and notes that a wide variety of approaches are available. In assessing these various approaches, it is argued that a useful first step is to consider what c...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.6.593

    authors: Carter R,Vos T,Moodie M,Haby M,Magnus A,Mihalopoulos C

    更新日期:2008-12-01 00:00:00

  • HRQOL and subjective well-being: noncomplementary forms of outcome measurement.

    abstract::This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.4.413

    authors: Cummins RA,Lau AL,Stokes M

    更新日期:2004-08-01 00:00:00

  • The minimum clinically important difference for EQ-5D index: a critical review.

    abstract::The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.894462

    authors: Coretti S,Ruggeri M,McNamee P

    更新日期:2014-04-01 00:00:00

  • Corneal transplantation using the Descemet's stripping endothelial keratoplasty technique.

    abstract::Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.2.137

    authors: Kharod BV,Carlson AN

    更新日期:2007-04-01 00:00:00

  • 10th World IHEA and ECHE Joint Congress: health economics in the age of longevity.

    abstract::The 10th consecutive World Health Economics conference was organized jointly by International Health Economics Association and European Conference on Health Economics Association and took place at The Trinity College, Dublin, Ireland in July 2014. It has attracted broad participation from the global professional commu...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type:

    doi:10.1586/14737167.2014.967220

    authors: Jakovljevic MB,Getzen TE,Torbica A,Anegawa T

    更新日期:2014-12-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • The power of r - pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?

    abstract::The pharmaceutical sector has been established as the primary cost driver in health. The scope of this paper is to explore the drivers of pharmaceutical expenditure in Cyprus by decomposing sales and assessing impact of prices, volumes and substitution effect. We used a statistical approach to decompose the growth of ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2014.889565

    authors: Petrou P

    更新日期:2014-04-01 00:00:00

  • Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions.

    abstract::Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.12.24

    authors: Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

    更新日期:2012-06-01 00:00:00

  • Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa.

    abstract::The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1256775

    authors: Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

    更新日期:2017-04-01 00:00:00